Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction |
| |
| Authors: | Eswar Krishnan Bhavik J Pandya Bharathi Lingala Ali Hariri Omar Dabbous |
| |
| Affiliation: | (1) Department of Medicine, Stanford University School of Medicine, 1000 Welch Rd, Suite 203, Palo Alto, CA 94304, USA;(2) Takeda Pharmaceuticals International, Inc., One Takeda Parkway, Deerfield, IL 60015, USA;(3) Takeda Pharmaceuticals North America, Inc., One Takeda Parkway, Deerfield, IL 60015, USA |
| |
| Abstract: | Introduction Patients with a history of myocardial infarction (MI) are often at risk for complications, including subsequent MI and death. Use of prognostic markers may aid in preventing these poor outcomes. Hyperuricemia is associated with increased risk for coronary heart disease (CHD) and/or mortality; however, it is unknown if serum urate (sUA) levels predict outcomes in patients with previous MI. The purpose of this study was to assess hyperuricemia as a biomarker of CHD outcomes in such patients. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
